We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

altona Diagnostics GmbH

altona Diagnostics GmbH develops and commercializes real-time PCR based assays and molecular diagnostic test solution... read more Featured Products: More products

Download Mobile App




Prolonged Maternal Zika Viremia Evaluated for Adverse Perinatal Outcomes

By LabMedica International staff writers
Posted on 10 Feb 2021
The recent worldwide epidemic confirmed maternal–fetal transmission of Zika virus (ZIKV) and its association with adverse perinatal outcomes, particularly severe central nervous system lesions and fetal losses.

ZIKV is detectable in maternal blood by reverse transcription polymerase chain reaction (RT-PCR) during the acute phase of infection. More...
ZIKV viremia usually lasts from two days before to 16 days after symptom onset. The median time of ZIKV RNA clearance is five days.

A team of medical scientists led by those at Lausanne University Hospital (Lausanne, Switzerland) carried out a prospective cohort study in French Guiana and enrolled Zika virus–infected pregnant women with a positive PCR result at inclusion and non-infected pregnant women; both groups underwent serologic testing in each trimester and at delivery during January–July 2016. Prolonged viremia was defined as ongoing virus detection >30 days post-infection.

The team performed molecular and serologic testing using the RealStar Zika Kit (Altona Diagnostics GmbH, Hamburg, Germany) for RT-PCR, in-house IgM and IgG antibody-capture ELISA, and microneutralization assays for serologic testing. The limit of detection for serum samples tested using the RealStar Zika Kit was 0.61 copies/μL (95% CI 0.39–1.27). A cycle threshold (Ct) value <37 was considered positive.

The team reported that adverse outcomes (fetal loss or neurologic anomalies) were more common in fetuses and neonates from mothers with prolonged viremia (40.0%) compared with those from infected mothers without prolonged viremia (5.3%, adjusted relative risk [aRR] 7.2 [95% CI 0.9–57.6]) or those from non-infected mothers (6.6%, aRR 6.7 [95% CI 3.0–15.1]). Congenital infections were confirmed more frequently in fetuses from mothers with prolonged viremia (9/15 [60.0%]) when compared with those from infected mothers without prolonged viremia (5/19 [26.3%], RR 2.3 [95% CI 1.0–5.4]) and non-infected mothers (0/332 [0.0%]).

The authors concluded that prolonged maternal ZIKV viremia could be a marker for an increased risk for maternal–fetal transmission and subsequent adverse perinatal outcomes. Even if prolonged maternal viremia is not consistently present in cases of congenital infection, it might reflect active viral replication in the fetal–placental compartment and should lead to an enhanced prenatal and neonatal follow-up. The study was published in the February 2021 issue of the journal Emerging Infectious Diseases.

Related Links:
Lausanne University Hospital
Altona Diagnostics GmbH



New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Collection and Transport System
PurSafe Plus®
New
Gold Member
Hematology Analyzer
Medonic M32B
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Colorectal cancer under the microscope (Photo courtesy of Adobe Stock)

Unique Microbial Fingerprint to Improve Diagnosis of Colorectal Cancer

Colorectal cancer is the fourth most common cancer in the UK and the second deadliest. New research has revealed that it carries a unique microbial fingerprint, which could help doctors better understand... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.